Skip to main content
Premium Trial:

Request an Annual Quote

CLC Bio Partners with SciEngines to Offer FPGA-Accelerated Bioinformatics

Premium

CLC Bio said this week that it is partnering with high-performance computing firm SciEngine to integrate its server and desktop-based sequence analysis software tools with SciEngines' field programmable gate array-based platform.

Initially, SciEngines' Rivyera system will offer implementations of Blastn, Blastp, and the Smith-Waterman algorithm, with other algorithms added later, CLC Bio said.

The platform can offer up to 128 FPGAs per machine and scales to 1,792 FPGAs per rack. It also offers up to 320 gigabytes of distributed random access memory and up to 128 GB of shared memory with over 100 GB/s total bandwidth.

Preliminary Blastp runs to align 920,000 amino acids from the black cottonwood tree, Populus trichocarpa, to a database demonstrated a 188-fold increase in speed using a Rivyera S3-5000 computer with 64 FPGA chips when compared to a Xeon E5520 core, Jost Bissel, SciEngines' chief software architect, said in a statement.

He also said that the company has seen a similar speedup "in early benchmark tests of Blastn," adding that "we expect both Blast implementations to be accelerated even further before the final release."

Last year, CLC Bio's competitor, Auckland, NZ-based Biomatters said it was partnering with ActiveMotif's TimeLogic to allow users of its Geneious Server software to run bioinformatics jobs on Time Logic's accelerated DeCypher system, a field programmable gate array-based technology (BI 1/14/2011).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.